Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma.

By A. Weeraratna, Yuan Jiang, G. Hostetter, K. Rosenblatt, P. Duray, M. Bittner, J. Trent. Cancer Cell, 2002

974 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Coexpression analysis of human genes across many microarray data sets. (2004, background): “Many of the other genes in this cluster have identified or suspected roles in the regulation of cell motility or tumor cell invasiveness (including DDR1, SPINT2, HRIHFB2122, TACSTD1, and WNT5A; Vogel et al. 1997; Seipel et al. 2001; Weeraratna et al. 2002).”
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies (2023, background): “456 The phenomenon of EMT observed in cancer cells bears a striking resemblance to phenotypic switching.”
Purified Wnt5a Protein Activates or Inhibits β-Catenin–TCF Signaling Depending on Receptor Context (2006, background): “This ability of Wnt5a to toggle between two considerably diverse forms of signaling is particularly intriguing when one considers that Wnt5a has been classified as both a tumor suppressor and an oncogene in various cell types [57–59].”
WNT and β-catenin signalling: diseases and therapies (2004, background): “Independent of tumour-suppressor roles, in other cancers such as melanoma there is evidence that WNT5A and WNT11 might act through the WNT/calcium pathway to promote increased cell motility and invasiveness, paving the way for future studies on the role of WNT signalling in metastasi”